ArticleScientific reports2025
Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the increasing availability of hemp-derived products for recreational and medicinal use, it is imperative to understand the hepatotoxicity of the naturally occurring phytocannabinoids. Though, traditionally animal models or in vitro techniques are used to evaluate hepatotoxicity, these methods often fail due to the species differences and lack of the needed complexity. Thus, this study investigated the hepatotoxicity potential of Cannabidiol (CBD), Cannabinol (CBN), Cannabichromene (CBC), and Cannabigerol (CBG) using the Emulate Quad-Culture Liver-Chip model. Liver-Chips were dosed with three concentrations (0.24, 3, or 4.7 µM) of each cannabinoid for 7 days continuously, and acetaminophen (APAP) at 1, 3 or 10 mM dose was also tested as positive control. CBD, CBN, and CBG demonstrated the lowest hepatotoxic potential, as evidenced by unchanged liver injury markers and albumin secretion. CBN at the mid and high dose and CBD at the high dose began to show signs of toxicity on day 7 as observed through morphological changes (CBN) and proinflammatory cytokine and LDH release (CBD), suggesting that increased exposure may result in more severe toxicity. CBC treatment caused increased lactate dehydrogenase (LDH), cytokine release, and decreased albumin production, suggesting moderate hepatotoxicity. Liver-Chip also revealed varying adverse effects of cannabinoids on reactive oxygen species (ROS) and mitochondrial function in both hepatocytes and non-parenchymal cells (NPCs), giving further insights into the mechanism of liver injury. These results indicated differences in cannabinoid toxicity profiles while demonstrating the Liver-Chip model as an alternative tool for live toxicity screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.